Artelo Biosciences a Finalist in J&J Dermatology Innovation Challenge
Clinical-stage pharmaceutical company, Artelo Biosciences, Inc. (Nasdaq: ARTL), has been named a finalist in Johnson & Johnson’s (NYSE: JNJ) Innovation Challenge in dermatology. The event is by invitation only and seeks novel approaches to treating atopic dermatitis from companies around the world.
The company is developing ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN).
Artelo has demonstrated ART26.12’s positive effects in preclinical psoriasis models. In vitro, ART26.12 was found to reduce oxidative stress and inflammation and to increase antimicrobial peptides in reconstructed human epidermis. In vivo, oral treatment with ART26.12 reduced scaling, skin thickness, and histopathological signs of damage.
Dr. Andrew Yates, Chief Scientific Officer of Artelo, said, “We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team. J&J’s stated evaluation criteria including uniqueness, feasibility, development plan viability, and potential impact to human health validates the differentiated potential of our novel Fatty-Acid Binding Protein 5 (FABP5) target platform. We believe that targeting FABP5 with inhibitors such as ART26.12, may apply to a wide range of indications …including dermatological conditions.”
Epidermal FABP is highly expressed in skin and immune cells and plays a key role in skin cell homeostasis. FABP5 is upregulated in numerous dermatological conditions, promoting inflammation and correlating with disease severity.
Artelo presented preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
